Greco FA (2019) Cancer of unknown primary site. DeVita, hellman, and rosenberg’s cancer: principles & practice of oncology. 11th edition. Wolters Kluwer, Philadelphia, pp 1720–37

Google Scholar 

Losa F, Soler G, Casado A et al (2018) SEOM clinical guideline on unknown primary cancer (2017). Clin Transl Oncol 20(1):89–96

Article  CAS  PubMed  Google Scholar 

Oien KA (2009) Pathologic evaluation of unknown primary cancer. Semin Oncol 36(1):8–37

Article  CAS  PubMed  Google Scholar 

Wick MR (2008) Immunohistochemical approaches to the diagnosis of undifferentiated malignant tumors. Ann Diagn Pathol 12(1):72–84

Article  PubMed  Google Scholar 

Fatima N, Zaman MU, Zaman A et al (2020) Detection efficiency of (18)F-flourodeoxyglucose positron emission tomography/computed tomography for primary tumors in patients with carcinoma of unknown primary. World J Nucl Med 19(1):47–51

Article  PubMed  Google Scholar 

van de Wouw AJ, Jansen RL, Speel EJ et al (2003) The unknown biology of the unknown primary tumour: a literature review. Ann Oncol 14(2):191–196

Article  PubMed  Google Scholar 

Kamposioras K, Pentheroudakis G, Pavlidis N (2013) Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks. Eur J Clin Invest 43(5):491–500

Article  CAS  PubMed  Google Scholar 

Mohrmann L, Werner M, Oles M et al (2022) Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity. Nat Commun 13(1):4485

Article  PubMed  PubMed Central  Google Scholar 

Handorf CR, Kulkarni A, Grenert JP et al (2013) A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. Am J Surg Pathol 37(7):1067–1075

Article  PubMed  PubMed Central  Google Scholar 

Ross JS, Wang K, Gay L et al (2015) Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol 1(1):40–49

Article  PubMed  Google Scholar 

Gatalica Z, Millis SZ, Vranic S et al (2014) Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. Oncotarget 5(23):12440–12447

Article  PubMed  PubMed Central  Google Scholar 

Kato S, Alsafar A, Walavalkar V et al (2021) Cancer of unknown primary in the molecular era. Trends Cancer 7(5):465–477

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dermawan JK, Rubin BP (2021) The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary(✰): molecular profiling of metastatic cancer of unknown primary. Semin Diagn Pathol 38(6):193–198

Article  PubMed  Google Scholar 

Pavlidis N (2003) Cancer of unknown primary: biological and clinical characteristics. Ann Oncol 14(Suppl 3):11–8

Article  Google Scholar 

Amela EY, Lauridant-Philippin G, Cousin S et al (2012) Management of “unfavourable” carcinoma of unknown primary site: synthesis of recent literature. Crit Rev Oncol Hematol 84(2):213–223

Article  PubMed  Google Scholar 

Pentheroudakis G, Stoyianni A, Pavlidis N (2011) Cancer of unknown primary patients with midline nodal distribution: midway between poor and favourable prognosis? Cancer Treat Rev 37(2):120–126

Article  PubMed  Google Scholar 

Ishida Y (2020) PD-1: its discovery, involvement in cancer immunotherapy, and beyond. Cells. https://doi.org/10.3390/cells9061376

Article  PubMed  PubMed Central  Google Scholar 

Balar AV, Weber JS (2017) PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother 66(5):551–564

Article  CAS  PubMed  PubMed Central  Google Scholar 

Darvin P, Toor SM, Sasidharan Nair V et al (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 50(12):1–11

Article  PubMed  Google Scholar 

Shiravand Y, Khodadadi F, Kashani SMA et al (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29(5):3044–3060

Article  PubMed  PubMed Central  Google Scholar 

Li K, Luo H, Huang L et al (2020) Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int 20:16

Article  PubMed  PubMed Central  Google Scholar 

Marcus L, Lemery SJ, Keegan P et al (2019) FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res 25(13):3753–3758

Article  CAS  PubMed  Google Scholar 

Harris PA, Taylor R, Thielke R et al (2009) Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381

Article  PubMed  Google Scholar 

Massard C, Loriot Y, Fizazi K (2011) Carcinomas of an unknown primary origin–diagnosis and treatment. Nat Rev Clin Oncol 8(12):701–710

Article  CAS  PubMed  Google Scholar 

De Marchi P, Leal LF, Duval da Silva V et al (2021) PD-L1 expression by tumor proportion score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC). J Clin Pathol 74(11):735–40

Article  PubMed  Google Scholar 

Kulangara K, Zhang N, Corigliano E et al (2019) Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med 143(3):330–337

Article  CAS  PubMed  Google Scholar 

Xie T, Zhang Z, Zhang X et al (2021) Appropriate PD-L1 Cutoff value for gastric cancer immunotherapy: a systematic review and meta-analysis. Front Oncol 11:646355

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carcano FM, Lengert AH, Vidal DO et al (2016) Absence of microsatellite instability and BRAF (V600E) mutation in testicular germ cell tumors. Andrology 4(5):866–872

Article  CAS  PubMed  Google Scholar 

Pavlidis N, Briasoulis E, Hainsworth J et al (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39(14):1990–2005

Article  CAS  PubMed  Google Scholar 

Greco FA, Pavlidis N (2009) Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol 36(1):65–74

Article  CAS  PubMed  Google Scholar 

Kim CS, Hannouf MB, Sarma S et al (2018) Survival outcome differences based on treatments used and knowledge of the primary tumour site for patients with cancer of unknown and known primary in Ontario. Curr Oncol 25(5):307–316

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350–1355

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hainsworth JD, Greco FA (2018) Cancer of unknown primary site: new treatment paradigms in the era of precision medicine. Am Soc Clin Oncol Educ Book 38:20–25

Article  PubMed  Google Scholar 

Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14(4):847–856

Article  CAS  PubMed  Google Scholar 

Kerr KM, Tsao MS, Nicholson AG et al (2015) Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol 10(7):985–989

Article  CAS  PubMed  Google Scholar 

Koomen BM, Badrising SK, van den Heuvel MM et al (2020) Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review. Histopathology 76(6):793–802

Article  PubMed  PubMed Central  Google Scholar 

Grossman JE, Vasudevan D, Joyce CE et al (2021) Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor. Oncogene 40(8):1393–1395

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davis AA, Patel VG (2019) The role of PD-L1 expression as a predictive biomarker: an analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer 7(1):278